Maria Inmaculada
Heras Fernando
Asociado Ciencias de la Salud
![Foto de Maria Inmaculada](/img/uploaded/88527de33e5c8d37fef652174b06ccfd.jpeg)
![Foto de Institut d'Investigacions Biomèdiques August Pi i Sunyer](/img/noimage_org.png)
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (2)
2015
-
Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML
American Journal of Clinical Pathology, Vol. 144, Núm. 3, pp. 484-492
2013
-
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients
British Journal of Haematology, Vol. 162, Núm. 4, pp. 474-482